New SPECT tracers: Example of tracers of proteoglycans and melanin;Nouveaux traceurs TEMP : exemple des traceurs des protéoglycanes et de la mélanine

Medecine Nucleaire

Volumn 33, Issue 3, 2009, Pages 161-167

  Cachin, F ^a,b   Chezal, J M ^b   Miot Noirault, E ^b   Moins, N ^b   Auzeloux, P ^b   Vidal, A ^b   Bonnet Duquennoy, M ^b   Boisgard, S ^b,c   Filaire, M ^b   Mestas, D ^a   Kelly, A ^a   Merlin, C ^a   Redini, F ^d   D'Incan, M ^b,c   Madelmont, J C ^b   Veyre, A ^a   Maublant, J ^a,b  

^a CRLCC Jean Perrin   (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

^c SERVICE DE RHUMATOLOGIE   (France)

^d Universite de Nantes   (France)

Author keywords

Arthritis; Chondrosarcoma; Iodobenzamides; Melanoma; Proteoglycans

Indexed keywords

BENZAMIDE DERIVATIVE; FLUORODEOXYGLUCOSE F 18; ICF 01012; MELANIN; N [2 (DIETHYLAMINO)ETHYL] 2 IODOBENZAMIDE I 125; N [2 (DIETHYLAMINO)ETHYL] 4 IODOBENZAMIDE I 125; N [2 (DIETHYLAMINO)ETHYL] 6 IODOQUINOXALINE 2 CARBOXAMIDE I 125; N TRIETHYLAMMONIUM 3 PROPYLANE N5 TC 99M; PROTEOGLYCAN; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; UNCLASSIFIED DRUG;

BRAIN SCINTISCANNING; CANCER STAGING; CHONDROSARCOMA; CLINICAL TRIAL; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG STABILITY; HUMAN; ISOTOPE LABELING; JOINT SCINTISCANNING; MELANOMA; METASTASIS; NONHUMAN; OSTEOARTHRITIS; SCINTILLATION CAMERA; SEMICONDUCTOR; SHORT SURVEY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 61849098813     PISSN: 09281258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mednuc.2009.01.003     Document Type: Short Survey

References (46)

1. Reginster J.Y. The prevalence and burden of arthritis. Rheumatology 41 Suppl 1 (2002) 3-6
2. Enquête de l'Insee et du CREDES 1991-1992.
3. Pelletier J.P., and Martel-Pelletier J. Therapeutic targets in osteoarthritis: from today to tomorrow with new imaging technology. Ann Rheum Dis 62 Suppl 2 (2003) ii79-ii82
4. Roach H.I., Aigner T., Soder S., Haag J., and Welkerling H. Pathobiology of osteoarthritis: pathomechanisms and potential therapeutic targets. Curr Drug Targets 8 (2007) 271-282
5. Garrigue H., Maurizis J.C., Nicolas C., Madelmont J.C., Godeneche D., Hulot T., et al. Disposition and metabolism of two acetylcholinesterase reactivators, pyrimidoxime and HI6, in rats submitted to organophosphate poisoning. Xenobiotica 20 (1990) 699-709
6. Maurizis J.C., Ollier M., Nicolas C., Madelmont J.C., Garrigue H., and Veyre A. In vitro binding of oxime acetylcholinesterase reactivators to proteoglycans synthesized by cultured chondrocytes and fibroblasts. Biochem Pharmacol 17 (1992) 1927-1933
7. 14C-labeled pancuronium bromide in rats. Chem Pharm Bull 22 (1974) 2502-2510
8. 99mTc]polyazamacrocycles, potential radiotracers for cartilage imaging. J Labelled Cpd Radiopharm 43 (2000) 585-594
9. Madelmont JC, Giraud I, Nicolas C, Maurizis JC, Rapp M, Ollier M, et al. Novel quaternary ammonium derivatives, method for preparing same and pharmaceutical use for treatment or diagnosis of pathologies affecting cartilage. Brevet WO2001000621, 2001.
10. Maurizis J.C., Rapp M., Nicolas C., Ollier M., Verny M., and Madelmont J.C. Disposition in rats of N-pyridinium-propyl-cyclam, N-triethylammonium-propyl-cyclam, and N-[Triethylammonium]-3-propyl-[15]ane-N5, potential cartilage imaging agents. Drug Metab Dispos 28 (2000) 418-422
11. Nicolas C., Verny M., Giraud I., Ollier M., Rapp M., Maurizis J.C., et al. New quaternary ammonium oxicam derivatives targeted toward cartilage: synthesis, pharmacokinetic studies, and antiinflammatory potency. J Med Chem 16 (1999) 5235-5240
12. Ollier M., Maurizis J.C., Nicolas C., Bonafous J., de Latour M., Veyre A., et al. Joint scintigraphy in rabbits with 99mtc-N-[3-(triethylammonio)propyl]-15ane-N5, a new radiodiagnostic agent for articular cartilage imaging. J Nucl Med 42 (2001) 141-145
13. Miot-Noirault E., Vidal A., Auzeloux P., Madelmont J.C., Maublant J., and Moins N. First In Vivo SPECT imaging of Mouse Femorotibial Cartilage using 99mTc-NTP 15-5. Mol Imaging 7 (2008) 263-271
14. Miot-Noirault E., Vidal A., Pastoureau P., Bonafous J., Chomel A., Sarry L., et al. Early detection and monitoring of cartilage alteration in the experimental meniscectomised guinea pig model of osteoarthritis by 99mTc-NTP 15-5 scintigraphy. Eur J Nucl Med Mol Imaging 34 (2007) 1280-1290
15. Pastoureau P., Leduc S., Chomel A., and De Ceuninck F. Quantitative assessment of articular cartilage and subchondral bone histology in the meniscectomized guinea pig model of osteoarthritis. Osteoarthritis Cartilage 11 (2003) 412-423
16. Adams M.E., Matyas J.R., Huang D., and Dourado G.S. Expression of proteoglycans and collagen in the hypertrophic phase of experimental osteoarthritis. J Rheumatol Suppl 43 (1995) 94-97
17. Sandell L.J., and Aigner T. Articular cartilage and changes in arthritis. An introduction: cell biology of osteoarthritis. Arthritis Res 3 (2001) 107-113
18. Marco R.A., Gitelis S., Brebach G.T., and Healey J.H. Cartilage tumors: evaluation and treatment. J Am Acad Orthop Surg 8 (2000) 292-304
19. Miot-Noirault E, Gouin F, Vidal A, Rapp M, Maublant J, Askienazy S, et al. First preclinical imaging of primary cartilage neoplasm and its local recurrence using 99mtc-ntp 15-5 radiotracer. J Nucl Med 2009 sous presse.
20. Standard Option Recommendation 2005, FNLCC.
21. Nguyen A.T., Akhurst T., Larson S.M., Coit D.G., and Brady M.S. PET Scanning with (18)F 2-Fluoro-2-Deoxy-D-Glucose (FDG) in Patients with Melanoma. Benefits and Limitations. Clin Positron Imaging 2 (1999) 93-98
22. Siccardi A.G. Tumor immunoscintigraphy by means of radiolabeled monoclonal antibodies: multicenter studies of the Italian National Research Council Special Project "Biomedical Engineering". Cancer Res 1 Suppl 3 (1990) 899s-903s
23. Blower P.J., Costa D.C., Lane D.M., Lui D., Brown R.S., Ell P.J., et al. Early detection of melanoma metastases with radioiodinated methylene blue. Eur J Nucl Med 25 (1998) 1322-1329
24. Salopek T.G., Scott J.R., Joshua A.V., Smylie M., Logus J.W., Morin C.A., et al. Radioiodinated N-[3-(4-morpholino)propyl]-N-methyl-2-hydroxy-5-iodo-3-methylbenzylamine (ERC9): a new potential melanoma imaging agent. Eur J Nucl Med 28 (2001) 408-417
25. Moreau M.F., Parry D., Michelot J., Labarre P., Madelmont J.C., Veyre A., et al. Synthèse, étude chez le rat, de composés radioiodés utilisables pour l'exploration du système nerveux central. Eur J Med Chem 21 (1986) 423-431
26. Michelot J.M., Moreau M.F., Labarre P.G., Madelmont J.C., Veyre A.J., Papon J.M., et al. Synthesis and evaluation of new iodine-125 radiopharmaceuticals as potential tracers for malignant melanoma. J Nucl Med 32 (1991) 1573-1580
27. Moreau M.F., Michelot J., Papon J., Bayle M., Labarre P., Madelmont J.C., et al. Synthesis, radiolabeling, and preliminary evaluation in mice of some (N-diethylaminoethyl)-4-iodobenzamide derivatives as melanoma imaging agents. Nucl Med Biol 22 (1995) 737-747
28. Moreau MF, Michelot J, Veyre A, Madelmont JC, Godeneche D, Labarre P, et al. Agents pour le diagnostic et le traitement des mélanomes, dérivés halogénés utilisables comme de tels agents et leur préparation. Brevet FR2642972, 1990.
29. Moreau MF, Michelot J, Veyre A, Madelmont JC, Godeneche D, Labarre P, et al. Agents for diagnosing and treating melanomas, aromatic halogenated derivatives usable as such agents and their preparation. Brevets US5190741 et EP0458886, 1990.
30. Brandau W., Niehoff T., Pulawski P., Jonas M., Dutschka K., Sciuk J., et al. Structure distribution relationship of iodine-123-iodobenzamides as tracers for the detection of melanotic melanoma. J Nucl Med 37 (1996) 1865-1871
31. Nicholl C., Mohammed A., Hull W.E., Bubeck B., and Eisenhut M. Pharmacokinetics of iodine-123-IMBA for melanoma imaging. J Nucl Med 38 (1997) 127-133
32. Larisch R., Schulte K.W., Vosberg H., Ruzicka T., and Müller-Gärtner H.W. Differential accumulation of iodine-123-iodobenzamide in melanotic and amelanotic melanoma metastases in vivo. J Nucl Med 39 (1998) 996-1001
33. Brenner W., Klomp H.J., Bohuslavizki K.H., Szonn B., Kampen W.U., and Henze E. Limited sensitivity of iodine-123-2-hydroxy-3-iodo-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl] benzamide whole-body scintigraphy in patients with malignant melanoma: a comparison with thallium-201 imaging. Eur J Nucl Med 26 (1999) 1567-1571
34. Labarre P., Papon J., Moreau M.F., Moins N., Bayle M., Veyre A., et al. Melanin affinity of N-(2-diethylaminoethyl)-4-iodobenzamide, an effective melanoma imaging agent. Melanoma Res 12 (2002) 115-121
35. John C.S., Bowen W.D., Saga T., Kinuya S., Vilner B.J., Baumgold J., et al. A malignant melanoma imaging agent: synthesis, characterization, in vitro binding and biodistribution of iodine-125-(2-piperidinylaminoethyl)-4-iodobenzamide. J Nucl Med 34 (1993) 2169-2175
36. Pham T.Q., Greguric I., Liu X., Berghofer P., Ballantyne P., Chapman J., et al. Synthesis and evaluation of novel radioiodinated benzamides for malignant melanoma. J Med Chem 26 (2007) 3561-3572
37. Mansard S., Papon J., Moreau M.F., Miot-Noirault E., Labarre P., Bayle M., et al. Uptake in melanoma cells of [N-(2-diethylaminoethyl)-2-iodobenzamide], BZA2, an imaging agent for melanoma staging: relation to pigmentation. Nucl Med Biol 32 (2005) 451-458
38. Chehade F., de Labriolle-Vaylet C., Moins N., Moreau M.F., Papon J., Labarre P., et al. Secondary ion mass spectrometry as a tool for investigating radiopharmaceutical distribution at the cellular level: the example of I-BZA and (14)C-I-BZA. J Nucl Med 46 (2005) 1701-1706
39. Guerquin-Kern J.L., Hillion F., Madelmont J.C., Labarre P., Papon J., and Croisy A. Ultra-structural cell distribution of the melanoma marker iodobenzamide: improved potentiality of SIMS imaging in life sciences. Biomed Eng online 6 (2004) 10
40. Michelot J.M., Moreau M.F., Veyre A.J., Bonafous J.F., Bacin F.J., Madelmont J.C., et al. Phase II scintigraphic clinical trial of malignant melanoma and metastases with iodine-123-N-(2-diethylaminoethyl 4-iodobenzamide). J Nucl Med 34 (1993) 1260-1266
41. Moins N., D'Incan M., Bonafous J., Bacin F., Labarre P., Moreau M.F., et al. 123I-N-(2-diethylaminoethyl)-2-iodobenzamide: a potential imaging agent for cutaneous melanoma staging. Eur J Nucl Med 29 (2002) 1478-1484
42. Moins N., Papon J., Seguin H., Gardette D., Moreau M.F., and Labarre P. Synthesis, characterization and comparative biodistribution study of a new series of p-iodine-125 benzamides as potential melanoma imaging agents. Nucl Med Biol 28 (2001) 799-808
43. Madelmont JC, Chezal JM, Moins N, Teulade JC, Chavignon O. Labelled analogues of halobenzamides as radiophamraceuticals. Brevet WO2008012782, 2008.
44. Chezal J.M., Papon J., Labarre P., Lartigue C., Galmier M.J., Decombat C., et al. Evaluation of radiolabeled (hetero)aromatic analogues of N-(2-diethylaminoethyl)-4-iodobenzamide for imaging and targeted radionuclide therapy of melanoma. J Med Chem 51 (2008) 3133-3144
45. Bonnet-Duquennoy M, Papon J, Mishelanny F, Labarre P, Gardette M, Cayre A, Maublant J, Madelmont Jc, Chezal Jm, Moins N. [131I]ICF01012, a potential agent for targeted radionuclide therapy of melanoma. Abstracts 2008 World Molecular Imaging Congress, Nice, N° 810.
46. Labarre P., Papon J., Rose A.H., Guerquin-Kern J.L., Morandeau L., Wu T.D., et al. N.Melanoma affinity in mice and immunosuppressed sheep of [(125)I]N-(4-dipropylaminobutyl)-4-iodobenzamide, a new targeting agent. Nucl Med Biol 99 (2008) 783-791